GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
ileal bile acid transporter (IBAT), linerixibat, for treating adult patients with cholestatic pruritus associated with primary biliary cholangitis (PBC). The global GLISTEN study met its primary endpoint by showing that treatment with linerixibat led to a statistically significant improvement in monthly itch score as compared with placebo over 24 weeks. Per management, if successfully developed, linerixibat has the potential to become the first therapy indicated for treating itch associated with PBC globally. Year to date, shares of GSK have lost 9.7% compared with the industry's decline of 11.1%. Image Source: Zacks Investment Research The preliminary safety data from the ongoing GLISTEN study were similar to those seen in previous studies on linerixibat. Full data from the GLISTEN study is expected to be presented at a medical conference in the future. Cholestatic pruritus (relentless itch) is one of the most common symptoms of PBC, a rare autoimmune disease that might
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Moderna (MRNA) Q4 Earnings Report Preview: What To Look For [Yahoo! Finance]Yahoo! Finance
- IDEAYA announces expanded collaboration with Gilead Sciences [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at DZ Bank AG from a "hold" rating to a "buy" rating. They now have a $108.00 price target on the stock.MarketBeat
- February 2025's Undervalued Stock Selections For Potential Investment Opportunities [Yahoo! Finance]Yahoo! Finance
- Why Gilead Sciences (GILD) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 2/13/25 - Form 4
- 2/13/25 - Form 13F-HR
- 2/12/25 - Form 144
- GILD's page on the SEC website